Literature DB >> 24450589

Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.

Lourdes Encinas1, Heather O'Keefe, Margarete Neu, Modesto J Remuiñán, Amish M Patel, Ana Guardia, Christopher P Davie, Natalia Pérez-Macías, Hongfang Yang, Maire A Convery, Jeff A Messer, Esther Pérez-Herrán, Paolo A Centrella, Daniel Alvarez-Gómez, Matthew A Clark, Sophie Huss, Gary K O'Donovan, Fátima Ortega-Muro, William McDowell, Pablo Castañeda, Christopher C Arico-Muendel, Stane Pajk, Joaquín Rullás, Iñigo Angulo-Barturen, Emilio Alvarez-Ruíz, Alfonso Mendoza-Losana, Lluís Ballell Pages, Julia Castro-Pichel, Ghotas Evindar.   

Abstract

Tuberculosis (TB) is one of the world's oldest and deadliest diseases, killing a person every 20 s. InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis, is the target of the frontline antitubercular drug isoniazid (INH). Compounds that directly target InhA and do not require activation by mycobacterial catalase peroxidase KatG are promising candidates for treating infections caused by INH resistant strains. The application of the encoded library technology (ELT) to the discovery of direct InhA inhibitors yielded compound 7 endowed with good enzymatic potency but with low antitubercular potency. This work reports the hit identification, the selected strategy for potency optimization, the structure-activity relationships of a hundred analogues synthesized, and the results of the in vivo efficacy studies performed with the lead compound 65.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24450589     DOI: 10.1021/jm401326j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

1.  Discovery of Potent and Selective Inhibitors for ADAMTS-4 through DNA-Encoded Library Technology (ELT).

Authors:  Yun Ding; Heather O'Keefe; Jennifer L DeLorey; David I Israel; Jeffrey A Messer; Cynthia H Chiu; Steven R Skinner; Rosalie E Matico; Monique F Murray-Thompson; Fan Li; Matthew A Clark; John W Cuozzo; Christopher Arico-Muendel; Barry A Morgan
Journal:  ACS Med Chem Lett       Date:  2015-07-07       Impact factor: 4.345

2.  Discovery, SAR, and X-ray Binding Mode Study of BCATm Inhibitors from a Novel DNA-Encoded Library.

Authors:  Hongfeng Deng; Jingye Zhou; Flora S Sundersingh; Jennifer Summerfield; Don Somers; Jeffrey A Messer; Alexander L Satz; Nicolas Ancellin; Christopher C Arico-Muendel; Katie L Sargent Bedard; Arthur Beljean; Svetlana L Belyanskaya; Ryan Bingham; Sarah E Smith; Eric Boursier; Paul Carter; Paolo A Centrella; Matthew A Clark; Chun-Wa Chung; Christopher P Davie; Jennifer L Delorey; Yun Ding; G Joseph Franklin; LaShadric C Grady; Kenny Herry; Clare Hobbs; Christopher S Kollmann; Barry A Morgan; Laura J Pothier Kaushansky; Quan Zhou
Journal:  ACS Med Chem Lett       Date:  2015-07-21       Impact factor: 4.345

3.  Evaluating the Contribution of Transition-State Destabilization to Changes in the Residence Time of Triazole-Based InhA Inhibitors.

Authors:  Lauren A Spagnuolo; Sandra Eltschkner; Weixuan Yu; Fereidoon Daryaee; Shabnam Davoodi; Susan E Knudson; Eleanor K H Allen; Jonathan Merino; Annica Pschibul; Ben Moree; Neil Thivalapill; James J Truglio; Joshua Salafsky; Richard A Slayden; Caroline Kisker; Peter J Tonge
Journal:  J Am Chem Soc       Date:  2017-02-22       Impact factor: 15.419

Review 4.  The tuberculosis drug discovery and development pipeline and emerging drug targets.

Authors:  Khisimuzi Mdluli; Takushi Kaneko; Anna Upton
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

Review 5.  DNA-encoded chemistry: enabling the deeper sampling of chemical space.

Authors:  Robert A Goodnow; Christoph E Dumelin; Anthony D Keefe
Journal:  Nat Rev Drug Discov       Date:  2016-12-09       Impact factor: 84.694

6.  Direct inhibitors of InhA are active against Mycobacterium tuberculosis.

Authors:  Ujjini H Manjunatha; Srinivasa P S Rao; Ravinder Reddy Kondreddi; Christian G Noble; Luis R Camacho; Bee H Tan; Seow H Ng; Pearly Shuyi Ng; Ng L Ma; Suresh B Lakshminarayana; Maxime Herve; Susan W Barnes; Weixuan Yu; Kelli Kuhen; Francesca Blasco; David Beer; John R Walker; Peter J Tonge; Richard Glynne; Paul W Smith; Thierry T Diagana
Journal:  Sci Transl Med       Date:  2015-01-07       Impact factor: 17.956

7.  A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.

Authors:  Alexander L Perryman; Weixuan Yu; Xin Wang; Sean Ekins; Stefano Forli; Shao-Gang Li; Joel S Freundlich; Peter J Tonge; Arthur J Olson
Journal:  J Chem Inf Model       Date:  2015-02-17       Impact factor: 4.956

8.  Discovery and Optimization of Potent, Selective, and in Vivo Efficacious 2-Aryl Benzimidazole BCATm Inhibitors.

Authors:  Hongfeng Deng; Jingye Zhou; Flora Sundersingh; Jeffrey A Messer; Donald O Somers; Myriam Ajakane; Christopher C Arico-Muendel; Arthur Beljean; Svetlana L Belyanskaya; Ryan Bingham; Emily Blazensky; Anne-Benedicte Boullay; Eric Boursier; Jing Chai; Paul Carter; Chun-Wa Chung; Alain Daugan; Yun Ding; Kenny Herry; Clare Hobbs; Eric Humphries; Christopher Kollmann; Van Loc Nguyen; Edwige Nicodeme; Sarah E Smith; Nerina Dodic; Nicolas Ancellin
Journal:  ACS Med Chem Lett       Date:  2016-02-08       Impact factor: 4.345

9.  What is a "DNA-Compatible" Reaction?

Authors:  Marie L Malone; Brian M Paegel
Journal:  ACS Comb Sci       Date:  2016-03-23       Impact factor: 3.784

10.  Evolution of a thienopyrimidine antitubercular relying on medicinal chemistry and metabolomics insights.

Authors:  Shao-Gang Li; Catherine Vilchèze; Sumit Chakraborty; Xin Wang; Hiyun Kim; Monica Anisetti; Sean Ekins; Kyu Y Rhee; William R Jacobs; Joel S Freundlich
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.